As animal health shifts toward pharma and biotech-driven interventions, basic determinants like nutrition, exercise and stress are being sidelined despite their immense impact on both health-span and lifespan.
Original article by Melissa Smith, Outreach & Communications Officer, ANH International
Abbreviated version below edited by Mike Ames-Sikora, Senior Editor, ANH-USA. Read the full version at ANH International
Listen to the audio version of this article:
THE TOPLINE
- Animals are increasingly developing the same chronic diseases as humans, driven by factors such as ultra-processed diets, inactivity, toxin exposure, stress and intensive farming conditions.
- Animal health is becoming more pharmaceuticalized, with growing use of drugs, novel vaccine technologies and biotech platforms, while questions remain around long-term safety, transparency and food-chain exposure.
- We need a prevention-first approach, prioritizing species-appropriate nutrition, movement, lower toxin exposure, ecological health and resilient farming systems over managing disease primarily through technological and pharmaceutical intervention.
Something has gone quietly wrong in the lives of our precious pets and livestock. Dogs are developing obesity, type 2 diabetes, cardiovascular disease and cancer at rates that would have seemed extraordinary a generation ago. Cats are being prescribed thyroid medication and insulin. Dairy cows are suffering metabolic disorders with increasing frequency. And now, a San Francisco biotech startup is on the cusp of becoming the first company in history to bring a longevity drug to market— not for humans, but dogs.
This is not simply about devoted pet owners and medical progress. It’s a discussion about how the same forces driving the chronic disease epidemic in humans are now operating across the entire animal world — and how the pharmaceutical industry has identified this as one of the most lucrative growth markets of the coming decade. It also digs into the introduction of novel vaccine technologies into the animal health space that could potentially enter the human food chain, a global governance framework positioning animals, under the World Health Organization’s (WHO) ‘One Health’ initiative, as disease reservoirs requiring pharmaceutical management, along with the explicit use of companion animals as a stepping stone to human drugs. These threads are not separate. They are woven from the same cloth.
Animals Are Mirroring Human Diseases
A peer-reviewed study published in late 2025 documented a sharp global rise in non-communicable (chronic) diseases in animals — not just pets, but livestock and even wildlife under human care. The conditions were striking in their familiarity: obesity, type 2 diabetes, cardiovascular disease, degenerative joint disease and cancer, all increasing across species.
The factors identified as driving this are precisely those driving the human chronic disease crisis: ultra-processed diets, reduced physical activity, environmental pollutant exposure, chronic stress and selective breeding that prioritizes commercial traits over physiological resilience.
The same wave of precision-fermented foods that are entering the human food supply are starting to enter animal foods as well.
All chronic disease states have root causes. They are not simply the inevitable fate of an ageing animal. In nature, animals live well until they pass. They do not spend the last third of their lives limping with chronic disease. But, as with humans, well animals are of no interest to the pharmaceutical industry.
The Technology vs Nature: saRNA Vaccines and the Food Chain Question
We’re also seeing the rapid introduction of self-amplifying RNA (saRNA) vaccines into companion animals and livestock, with little public debate about long-term implications or entry into the human food chain. Here’s the kicker. These technologies are already in use!
Unlike conventional vaccines, saRNA constructs contain replication machinery derived from alphaviruses, allowing the RNA to amplify itself inside cells and prolong antigen production from very small doses. This increased biological activity is central to the technology’s commercial appeal, but also raises questions about biodistribution, persistence, reproductive transfer and long-term exposure that remain insufficiently studied in food-producing animals.
Regulators argue that withdrawal periods prevent residues entering the food chain, but these frameworks were designed for conventional pharmaceuticals rather than self-amplifying genetic constructs. Publicly available long-term toxicology and biodistribution data remain limited, particularly regarding repeated exposure across industrial farming systems.
Another problem is that veterinary approval pathways are often faster and less precautionary than those used in human medicine, creating incentives to scale novel biotech platforms first through animals before wider human application. Once deployed across livestock systems, exposure expands from millions of animals to entire populations of consumers — without labelling, informed consent or long-term post-market evidence.
This reflects a broader pattern: increasingly complex biological technologies are being introduced at industrial scale before foundational questions about necessity, transparency and long-term safety have been properly answered, and before comparative effectiveness research has been conducted on less intrusive alternatives like nutrition, physical activity, and stress reduction.
The Framework: One Health and Pharmaceutical Governance
These developments are not occurring in isolation. They are unfolding within the rapidly expanding framework of “One Health” — the WHO-backed model that links human, animal and environmental health into a single global management system.
On the surface, the idea sounds reasonable: human and animal health are clearly interconnected. But One Health is not simply a scientific observation. It is also a governance model, increasingly tied to pandemic preparedness, biosecurity surveillance and coordinated pharmaceutical intervention across species.
Under the One Health framework, animals are increasingly viewed primarily through the lens of pandemic risk. This creates a powerful institutional justification for expanding vaccine platforms, genomic tracking and novel biotech interventions throughout both companion animals and livestock.
The concern is that One Health risks becoming less about improving the underlying health of ecosystems and more about building a permanent infrastructure for pharmaceutical management at population scale.
Industrial farming, environmental toxicity, biodiversity loss and habitat destruction drive chronic disease and zoonotic risk, yet receive far less attention than surveillance and pharmaceutical responses. From an ANH perspective, One Health increasingly manages the consequences through centralized monitoring and rapid vaccine deployment rather than addressing root causes through resilient food systems, metabolic health, ecological restoration and prevention.
Prioritizing Animal Health
We already know a great deal about what keeps animals healthy: species-appropriate natural, evolutionary-rational nutrition, minimal ultra-processing, physical activity, reduced toxin exposure, lower chronic stress and greater genetic resilience. For livestock, in addition to that list, farming conditions themselves — crowding, confinement and feed quality — are primary determinants of health outcomes.
The same principles apply to humans. But prevention is far less commercially attractive than lifelong treatment.
The ‘System’ at Work
The underlying cycle is consistent: industrial systems generate chronic disease, pharmaceuticals manage it, and regulation accelerates adoption.
Pet medicalization points to a broader shift—towards treating ageing, immunity and metabolism as conditions requiring continuous technological control rather than outcomes of lifestyle and environment. What is tested in animals today anticipates how human health will be defined tomorrow. The counter-position is preventive health rooted in evolutionary rational nutrition, movement, stress management and environmental integrity.
Please circulate this article among your networks.
